Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines (NASDAQ: PRAX) has announced equity grants to six new non-executive employees under its 2024 Inducement Plan. The compensation package includes:
- Non-qualified stock options to purchase 2,000 shares of common stock
- Restricted stock unit awards covering 7,288 shares
The stock options were granted at $33.55 per share, matching PRAX's closing price on the grant date. The options will vest over four years, with 25% vesting after the first year and the remainder monthly over three years. Restricted stock units will vest in four equal annual installments. These grants comply with Nasdaq Listing Rule 5635(c)(4) as inducement awards for new employees.
Praxis Precision Medicines (NASDAQ: PRAX) ha annunciato concessioni azionarie a sei nuovi dipendenti non esecutivi nell'ambito del suo Piano di Induzione 2024. Il pacchetto retributivo include:
- Opzioni su azioni non qualificate per l'acquisto di 2.000 azioni ordinarie
- Assegnazioni di unità azionarie vincolate che coprono 7.288 azioni
Le opzioni su azioni sono state concesse a $33,55 per azione, corrispondente al prezzo di chiusura di PRAX nella data di concessione. Le opzioni matureranno nel corso di quattro anni, con il 25% che matura dopo il primo anno e il resto mensilmente per tre anni. Le unità azionarie vincolate matureranno in quattro rate annuali uguali. Queste concessioni sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) come premi di induzione per nuovi dipendenti.
Praxis Precision Medicines (NASDAQ: PRAX) ha anunciado concesiones de acciones a seis nuevos empleados no ejecutivos bajo su Plan de Inducción 2024. El paquete de compensación incluye:
- Opciones de acciones no calificadas para comprar 2,000 acciones ordinarias
- Premios de unidades de acciones restringidas que cubren 7,288 acciones
Las opciones de acciones se otorgaron a $33.55 por acción, coincidiendo con el precio de cierre de PRAX en la fecha de otorgamiento. Las opciones se adquirirán durante cuatro años, con el 25% adquiriéndose después del primer año y el resto mensualmente durante tres años. Las unidades de acciones restringidas se adquirirán en cuatro cuotas anuales iguales. Estas concesiones cumplen con la Regla de Cotización de Nasdaq 5635(c)(4) como premios de inducción para nuevos empleados.
프랙시스 프리시전 메디슨스 (NASDAQ: PRAX)는 2024 유도 계획에 따라 6명의 새로운 비임원 직원에게 주식 보상을 발표했습니다. 보상 패키지에는 다음이 포함됩니다:
- 2,000주를 구매할 수 있는 비자격 주식 옵션
- 7,288주를 포함하는 제한 주식 단위 보상
주식 옵션은 주당 $33.55에 부여되었으며, 이는 부여일의 PRAX 종가와 일치합니다. 옵션은 4년에 걸쳐 분할되어, 첫 해에 25%가 확정되고 나머지는 3년에 걸쳐 매월 확정됩니다. 제한 주식 단위는 4개의 동등한 연간 할부로 확정됩니다. 이러한 보상은 새로운 직원에 대한 유도 보상으로서 나스닥 상장 규칙 5635(c)(4)를 준수합니다.
Praxis Precision Medicines (NASDAQ: PRAX) a annoncé des attributions d'actions à six nouveaux employés non exécutifs dans le cadre de son Plan d'Induction 2024. Le package de rémunération comprend :
- Des options d'achat d'actions non qualifiées pour l'acquisition de 2 000 actions ordinaires
- Des attributions d'unités d'actions restreintes couvrant 7 288 actions
Les options d'achat d'actions ont été accordées à 33,55 $ par action, correspondant au prix de clôture de PRAX à la date d'attribution. Les options seront acquises sur une période de quatre ans, avec 25 % acquises après la première année et le reste mensuellement pendant trois ans. Les unités d'actions restreintes seront acquises en quatre versements annuels égaux. Ces attributions sont conformes à la règle de cotation Nasdaq 5635(c)(4) en tant que récompenses d'incitation pour de nouveaux employés.
Praxis Precision Medicines (NASDAQ: PRAX) hat Aktienvergaben an sechs neue nicht-executive Mitarbeiter im Rahmen seines Induktionsplans 2024 bekannt gegeben. Das Vergütungspaket umfasst:
- Nicht qualifizierte Aktienoptionen zum Kauf von 2.000 Stammaktien
- Auszeichnungen von eingeschränkten Aktieneinheiten für insgesamt 7.288 Aktien
Die Aktienoptionen wurden zu 33,55 $ pro Aktie gewährt, was dem Schlusskurs von PRAX am Tag der Gewährung entspricht. Die Optionen werden über vier Jahre vesten, wobei 25% nach dem ersten Jahr und der Rest monatlich über drei Jahre vesten. Eingeschränkte Aktieneinheiten werden in vier gleichen jährlichen Raten vesten. Diese Zuwendungen entsprechen der Nasdaq-Listing-Regel 5635(c)(4) als Induktionsauszeichnungen für neue Mitarbeiter.
- New talent acquisition with equity incentives indicates company growth
- Structured vesting schedule helps retain employees long-term
- Potential shareholder dilution from new equity grants
BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on March 3, 2025, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 2,000 shares of its common stock and restricted stock unit awards covering an aggregate of 7,288 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The stock options and restricted stock units were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
FAQ
What is the exercise price of PRAX stock options granted on March 3, 2025?
How many shares were included in PRAX's March 2025 inducement grants?
What is the vesting schedule for PRAX's March 2025 stock option grants?
How do the restricted stock units vest in PRAX's March 2025 inducement grants?
